Japan Generic Drugs Market Size Insights Forecasts to 2032
- The Japan Generic Drugs Market Size was valued at USD 9.35 Billion in 2022.
- The Market Size is Growing at a CAGR of 6.2% from 2022 to 2032.
- The Japan Generic Drugs Market Size is expected to reach USD 17.2 Billion by 2032.
- Japan is expected to Grow the fastest during the forecast period.
Get more details on this report -
The Japan Generic Drugs Market Size is expected to reach USD 17.2 Billion by 2032, at a CAGR of 6.2% during the forecast period 2022 to 2032.
Japan is a unique player in the global pharmaceutical landscape, acknowledged for its advanced technological achievements, long life expectancy, and robust healthcare system. Originally, Japan has prioritized new pharmaceuticals, with a lukewarm stance regarding generics. However, with the aging population and the government's emphasis on reducing healthcare costs, there has been a strategic shift toward encouraging the use of generic pharmaceuticals. To combat rising healthcare expenses, the Japanese government has actively promoted the use of generic medications. Policies and incentives have been established to hasten the adoption of generic drugs to achieve a higher rate of substitution. The quality of pharmaceuticals is highly valued in Japan. While generic pharmaceuticals are intended to be cost-effective, they are subjected to stringent quality controls to assure their safety and efficacy, hence maintaining public trust. Furthermore, Japan's increasingly aging population creates a high demand for pharmaceuticals. The usage of low-cost generic medications aids in the management of the country's rising healthcare costs. While Japan's generic drug market is expanding, issues include the need for additional education and awareness among healthcare professionals and the general public, as well as addressing any remaining concerns regarding the quality of generic medications.
This research report categorizes the market for Japan Generic Drugs Market based on various segments and regions and forecasts revenue Growth and analyzes trends in each submarket. The report analyses the key Growth drivers, opportunities, and challenges influencing the Japan Generic Drugs Market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Japan Generic Drugs Market.
Japan Generic Drugs Market Report Coverage
|Market Size in 2022:||USD 9.35 Billion|
|Forecast Period 2022-2032 CAGR:||6.2%|
|2032 Value Projection:||USD 17.2 Billion|
|Historical Data for:||2019-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||110|
|Segments covered:||By Type, By Application, By Distribution Channel and COVID-19 Impact.|
|Companies Covered:||Sawai Pharmaceuticals Co., Ltd., Hikari Pharmaceutical Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Towa Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Daiichi Sankyo, Astellas Pharma Inc., Eisai Co., Ltd., Shionogi & Company, Limited, Mitsubishi Tanabe Pharma, Asahi Kasei Corporation, Kyowa Kirin Co Ltd, Taisho Pharmaceutical Co., Ltd., Nippon Chemiphar Corporation, and other key vendors.|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth & Analysis.|
Get more details on this report -
Japan's healthcare spending has increased due to the country's Growing aging population. Generic drugs, because they are less expensive, are a feasible solution for meeting this demand without increasing healthcare expenditures. Recognizing the potential reductions offered by generics, the government has adopted laws encouraging their usage, hence fueling market expansion. The Pharmaceuticals and Medical Devices Agency (PMDA) ensures that generic pharmaceuticals fulfill the same stringent safety and efficacy standards as branded drugs. This builds consumer trust and facilitates greater adoption. Furthermore, as the general public becomes more aware of the efficacy and safety of generic pharmaceuticals that are equal to their branded equivalents, their acceptance and consumption have increased. While local manufacturers continue to dominate the market, multinational firms are also making progress. To be successful, they frequently work with local businesses or adapt to Japan-specific requirements.
- In 2022, the generic prescription medicines segment is witnessing a higher Growth rate over the forecast period.
Based on the type, the Japan Generic Drugs Market is segmented into generic prescription medicines, super generics, and biosimilars. Among these, the generic prescription medicines segment is witnessing a higher Growth rate over the forecast period. The Japanese government has actively promoted the use of generic pharmaceuticals as a cost-cutting solution for the country's national healthcare system. Generic drugs are typically less expensive than their branded versions, making them a more cost-effective option for both consumers and healthcare systems. With laws in place to encourage the use of generic drugs while lowering healthcare costs, generic prescription medicines have gained universal acceptance and adoption among healthcare providers and patients.
- In 2022, the cardiovascular diseases segment accounted for the largest revenue share of more than 37.8% over the forecast period.
On the basis of application, the Japan Generic Drugs Market is segmented into central nervous system disorders, respiratory diseases, hormones & related diseases, gastrointestinal diseases, cardiovascular diseases, infectious diseases, cancer, diabetes, and others. Among these, the cardiovascular diseases segment is dominating the market with the largest revenue share of 37.8% over the forecast period. These drugs are used to treat heart and blood vessel disorders such as hypertension, coronary artery disease, heart failure, arrhythmias, and others. Cardiovascular disorders continue to be the most prevalent cause of death worldwide, making this category significant in the Japanese generic medicine industry. With Japan's aging population and an increase in lifestyle-related factors, there has been a steady demand for therapeutic approaches for cardiovascular diseases. Furthermore, the high cost of branded cardiovascular drugs drives many people to generic alternatives, which are less expensive without jeopardizing efficacy.
- In 2022, the retail pharmacies segment accounted for the largest revenue share of more than 34.2% over the forecast period.
On the basis of distribution channel, the Japan Generic Drugs Market is segmented into hospitals pharmacies, retail pharmacies, and online pharmacies. Among these, the retail pharmacies segment is dominating the market with the largest revenue share of 34.2% over the forecast period. These outlets can be found in cities, villages, and even rural places throughout Japan. Many retail pharmacies in Japan sell health-related products, over-the-counter pharmaceuticals, and personal care items in addition to generic prescriptions. Face-to-face consultations at retail pharmacies are a favored choice for many Japanese consumers because of their accessibility, convenience, and confidence. Furthermore, because of the dense population distribution in areas such as Tokyo, Osaka, and Yokohama, retail pharmacies are easily accessible to a huge proportion of the population.
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Generic Drugs Market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Sawai Pharmaceuticals Co., Ltd.
- Hikari Pharmaceutical Co., Ltd.
- Nichi-Iko Pharmaceutical Co., Ltd.
- Fuji Pharma Co., Ltd.
- Meiji Seika Pharma Co., Ltd.
- Towa Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Astellas Pharma Inc.
- Eisai Co., Ltd.
- Shionogi & Company, Limited
- Mitsubishi Tanabe Pharma
- Asahi Kasei Corporation
- Kyowa Kirin Co Ltd
- Taisho Pharmaceutical Co., Ltd.
- Nippon Chemiphar Corporation
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2021 to 2032. Spherical Insights has segmented the Japan Generic Drugs Market based on the below-mentioned segments:
Japan Generic Drugs Market, By Type
- Generic Prescription Medicines
- Super Generics
Japan Generic Drugs Market, By Application
- Central Nervous System Disorders
- Respiratory Diseases
- Hormones & Related Diseases
- Gastrointestinal Diseases
- Cardiovascular Diseases
- Infectious Diseases
Japan Generic Drugs Market, By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Need help to buy this report?